JP4316787B2 - エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、 - Google Patents

エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、 Download PDF

Info

Publication number
JP4316787B2
JP4316787B2 JP2000356303A JP2000356303A JP4316787B2 JP 4316787 B2 JP4316787 B2 JP 4316787B2 JP 2000356303 A JP2000356303 A JP 2000356303A JP 2000356303 A JP2000356303 A JP 2000356303A JP 4316787 B2 JP4316787 B2 JP 4316787B2
Authority
JP
Japan
Prior art keywords
compound
aromatic
methyl
melting point
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000356303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001261662A (ja
JP2001261662A5 (https=
Inventor
剛 冨山
格 冨山
泰 冨山
敬子 黒岩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kotobuki Seiyaku Co Ltd
Original Assignee
Kotobuki Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kotobuki Seiyaku Co Ltd filed Critical Kotobuki Seiyaku Co Ltd
Priority to JP2000356303A priority Critical patent/JP4316787B2/ja
Priority to KR1020010000631A priority patent/KR20010070442A/ko
Priority to GB0100433A priority patent/GB2359082B/en
Priority to FR0100207A priority patent/FR2804681B1/fr
Priority to ES200100058A priority patent/ES2187261B2/es
Priority to DE10100772A priority patent/DE10100772B4/de
Priority to US09/756,701 priority patent/US6414001B2/en
Priority to CNB011047011A priority patent/CN1227231C/zh
Priority to IT2001MI000042A priority patent/ITMI20010042A1/it
Publication of JP2001261662A publication Critical patent/JP2001261662A/ja
Publication of JP2001261662A5 publication Critical patent/JP2001261662A5/ja
Application granted granted Critical
Publication of JP4316787B2 publication Critical patent/JP4316787B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2000356303A 2000-01-11 2000-11-22 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、 Expired - Fee Related JP4316787B2 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2000356303A JP4316787B2 (ja) 2000-01-11 2000-11-22 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
KR1020010000631A KR20010070442A (ko) 2000-01-11 2001-01-05 에테르 및 아미드 화합물 및 항당뇨병제로서의 그의 제제
GB0100433A GB2359082B (en) 2000-01-11 2001-01-08 Antidiabetic ether and amide compounds and preparation thereof
FR0100207A FR2804681B1 (fr) 2000-01-11 2001-01-09 Compose antidiabetique et procede pour sa production
DE10100772A DE10100772B4 (de) 2000-01-11 2001-01-10 Ether- und Amidverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Antidiabetika
US09/756,701 US6414001B2 (en) 2000-01-11 2001-01-10 Ether and amide compounds preparation thereof composition containing same and use thereof as antidiadetics
ES200100058A ES2187261B2 (es) 2000-01-11 2001-01-10 Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
CNB011047011A CN1227231C (zh) 2000-01-11 2001-01-11 作为抗糖尿病药的醚和酰胺类化合物及制备方法
IT2001MI000042A ITMI20010042A1 (it) 2000-01-11 2001-01-11 Composti di eteri e di ammidi e loro preparazione come antidiabetici

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000006106 2000-01-11
JP2000-6106 2000-01-11
JP2000356303A JP4316787B2 (ja) 2000-01-11 2000-11-22 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、

Publications (3)

Publication Number Publication Date
JP2001261662A JP2001261662A (ja) 2001-09-26
JP2001261662A5 JP2001261662A5 (https=) 2005-07-28
JP4316787B2 true JP4316787B2 (ja) 2009-08-19

Family

ID=26583525

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000356303A Expired - Fee Related JP4316787B2 (ja) 2000-01-11 2000-11-22 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、

Country Status (9)

Country Link
US (1) US6414001B2 (https=)
JP (1) JP4316787B2 (https=)
KR (1) KR20010070442A (https=)
CN (1) CN1227231C (https=)
DE (1) DE10100772B4 (https=)
ES (1) ES2187261B2 (https=)
FR (1) FR2804681B1 (https=)
GB (1) GB2359082B (https=)
IT (1) ITMI20010042A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2418104A1 (en) 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
AU2001284660A1 (en) 2000-08-23 2002-03-04 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
JP2004509084A (ja) 2000-08-23 2004-03-25 イーライ・リリー・アンド・カンパニー オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用
US7009057B2 (en) * 2001-04-26 2006-03-07 Zentiva A.S. Method for obtaining pioglitazone as an antidiabetic agent
HRP20031002A2 (en) 2001-06-07 2004-06-30 Lilly Co Eli Modulators of peroxisome proliferator activated receptors (ppar)
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
TWI281916B (en) 2001-10-25 2007-06-01 Lilly Co Eli Antitumor compounds and methods
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US20080045706A1 (en) * 2002-12-31 2008-02-21 Flynn Daniel L Anti-inflammatory medicaments
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
ES2297382T3 (es) 2003-02-14 2008-05-01 Eli Lilly And Company Derivados de sulfonamida como moduladores de ppar.
US7348453B2 (en) * 2003-09-04 2008-03-25 Mirus Bio Corporation Labile linkage for compound delivery to a cell
JP4175291B2 (ja) * 2004-05-12 2008-11-05 トヨタ自動車株式会社 車両の減速制御装置
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PL1650186T3 (pl) * 2004-10-22 2008-11-28 Bioprojet Soc Civ Nowe pochodne kwasów dikarboksylowych
CN101735048A (zh) * 2008-11-05 2010-06-16 上海慈瑞医药科技有限公司 具胰岛素增敏活性的水杨酸类化合物及其制备方法
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
US9388179B2 (en) 2012-10-26 2016-07-12 Merck Sharp & Dohme Corp. N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
CN112028833B (zh) * 2020-09-25 2022-07-05 西南大学 对氨基水杨酸唑类衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008652A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5239080A (en) * 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
WO1992003425A1 (en) * 1990-08-23 1992-03-05 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
TW245716B (https=) * 1992-12-28 1995-04-21 Takeda Pharm Industry Co
TW268952B (https=) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
CN1233241A (zh) * 1996-08-19 1999-10-27 日本烟草产业株式会社 丙酸衍生物及其用途
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
AU7052200A (en) * 1999-08-27 2001-03-26 Eli Lilly And Company Hypoglycemic sulfonyl pyrazolones and pyrazolines
US6617343B1 (en) * 1999-08-27 2003-09-09 Eli Lilly And Company Hypoglycemic N,N-arylsulfonylglycine compounds

Also Published As

Publication number Publication date
DE10100772B4 (de) 2005-09-22
ES2187261B2 (es) 2004-07-16
US20010008898A1 (en) 2001-07-19
GB2359082B (en) 2004-09-29
JP2001261662A (ja) 2001-09-26
GB2359082A (en) 2001-08-15
ES2187261A1 (es) 2003-05-16
CN1315320A (zh) 2001-10-03
FR2804681B1 (fr) 2004-06-25
CN1227231C (zh) 2005-11-16
FR2804681A1 (fr) 2001-08-10
DE10100772A1 (de) 2001-07-19
KR20010070442A (ko) 2001-07-25
ITMI20010042A1 (it) 2002-07-11
US6414001B2 (en) 2002-07-02
GB0100433D0 (en) 2001-02-21

Similar Documents

Publication Publication Date Title
JP4316787B2 (ja) エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
JP2611244B2 (ja) チアゾリジンジオン誘導体の製造法
NO323426B1 (no) Nytt 3-aryl-2-hydroksypropionsyrederivat, fremgangsmate for fremstilling derav samt anvendelse derav i terapi
JP2003517013A (ja) フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物
TW200521122A (en) Method of preparing 1,2,4-triazole compounds and intermediates thereof
JPS6341904B2 (https=)
FR2662692A1 (fr) Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique.
JP2000001431A (ja) 尿酸排泄剤
JP2004512326A5 (https=)
JP3642797B2 (ja) フェニルカルボキサミドイソオキサゾールの新誘導体及びそれらの塩類、それらの製造法及びこの製造法の新規な中間体、それらの薬剤としての用途並びにそれらを含有する製薬組成物
JPS6334154B2 (https=)
PT1502590E (pt) Derivados de oximas heterocíclicas, processo para a sua preparação, e sua utilização no tratamento do diabetes de tipo ii
TWI284127B (en) Cyclization process for substituted benzothiazole derivatives
JPH072848A (ja) モルホリンおよびチオモルホリン誘導体
DK175838B1 (da) Fremgangsmåde til fremstilling af 2,6-dichlordiphenylamineddikesyrederivater
JPH0256471A (ja) 新規な（ヘテロ）アリル置換ジアゾール誘導体、その製造方法および治療への適用
CN101068770B (zh) 制备6-取代的-1-甲基-1-h-苯并咪唑衍生物的方法及其合成中间体
JP3213576B2 (ja) 置換ピリジン
JP3272819B2 (ja) 安息香酸およびニコチン酸誘導体の製造方法
CA2022425C (en) 1,3,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
JP4167302B2 (ja) 新規ｎ―置換ピロリジン誘導体及びその製造法
EP0875499A2 (en) Process for the crystallisation of alkali metal salts of diformylamide
JP3968136B2 (ja) ３−（置換アミノメチル）−６−クロロピリジンの製造方法
JP4047949B2 (ja) ベンゾチアゾール誘導体の製法
CN117551012A (zh) 一种含苄基结构的取代酰基苯胺类化合物的制备方法

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20081022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081028

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090310

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090519

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090521

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120529

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees